Home > Healthcare > Pharmaceuticals > Finished Drug Form > Vaginitis Therapeutics Market

Vaginitis Therapeutics Market Size

  • Report ID: GMI7213
  • Published Date: Oct 2023
  • Report Format: PDF

Vaginal Therapeutics Market Size

Vaginitis Therapeutics Market size was around USD 3.6 billion in 2022 and is expected to reach USD 7.3 billion by 2032 with a CAGR of 7.6%. High prevalence of vaginal infections, growing awareness pertaining to women’s health and the availability of effective treatments, and various government and private initiatives are driving the demand.

 

Vaginitis Therapeutics Market

To understand key trends  
Download Free Sample
 

For instance, the National Institute of Allergy and Infectious Diseases (NIAID) funded scientists to develop a test for yeast infection to provide appropriate anti-fungal treatment in infected females. Thus, government-sponsored health programs often provide subsidized or free healthcare services, including diagnosis and treatment for vaginal infections, resulting to growing access for affected individuals. Further, the rising awareness about feminine hygiene, self-medication, easy of availability of over the counter drugs such as creams and gels is expected to foster the market trends.

 

Vaginitis therapeutics refer to the medical interventions and treatments used to manage and alleviate the symptoms of vaginitis, a common medical condition characterized by inflammation or irritation of the vagina. Vaginitis can be caused by various factors, including infections, hormonal imbalances, or irritants, and the choice of treatment depends on the underlying cause.

Authors: Mariam Faizullabhoy , Gauri Wani

Frequently Asked Questions (FAQ) :

Vaginitis therapeutics industry size was USD 3.6 billion in 2022 and is expected to reach USD 7.3 billion by 2032 due to the rising prevalence of vaginal infections, growing awareness pertaining to women’s health and the increasing availability of effective treatments worldwide.

The bacterial vaginosis disease type segment held 43.6% share of the vaginitis therapeutics industry in 2022 and is expected to register a significant CAGR from 2023-2032 on account of it being the most prevalent vaginal infection among women of reproductive age.

North America vaginitis therapeutics industry is expected to grow at 7.3% CAGR from 2023-2032 owing to a high prevalence of menopausal and postmenopausal women in the region.

Pfizer, Inc., Merck & Co., Novartis AG, Bayer AG, Lupin Pharmaceuticals, Inc., Sanofi SA, Dr. Reddy’s Laboratories Ltd, Sun Pharmaceuticals Pvt Ltd, Cipla Ltd, and Takeda Pharmaceuticals, are some of the major market worldwide.

Vaginitis Therapeutics Market Scope

Buy Now

Access to only 1 person; cannot be shared; cannot be printed
Access for 2 to 5 users only within same department of one company
Access to a company wide audience; includes subsidiary companies or other companies within a group of companies

Premium Report Details

  • Base Year: 2022
  • Companies covered: 11
  • Tables & Figures: 316
  • Countries covered: 9
  • Pages: 170
 Download Free Sample